High materiality8/10
Eton Pharmaceuticals initiated with a Buy at Canaccord
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Canaccord Genuity initiated coverage on ETON with a Buy rating; target price $60; current price $37.19.
- Canaccord initiates ETON with Buy; PT $60; price $37.19.
- Upside to $60 (~61%).
Key facts
- 01
Target: $60
- 02
Posted price: $37.19
- 03
Analyst firm: Canaccord Genuity
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.